
Comera Life Sciences Holdings, Inc. Common Stock
CMRA
CMRA: Comera Life Sciences Holdings Inc is a pre-clinical biotechnology company dedicated to promoting formulation science and technology to transform essential biologic medicines from intravenous to subcutaneous forms. Comera's internal portfolio of proprietary techniques known as the SQore platform is designed to potentially transform essential biologic medicines from intravenous (IV) to subcutaneous (SQ) forms, and optimize current versions of subcutaneous biologics, and produce biosimilar versions of existing subcutaneous products. It also collaborates with pharmaceutical and biotechnology companies, applying the SQore platform to the Company's partners' biologic medicines to deliver enhanced formulations that facilitate self-injectable care.
moreShow CMRA Financials
Recent trades of CMRA by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by CMRA's directors and management
Government lobbying spending instances
New patents grants
-
Patent Title: Viscosity-reducing compounds for protein formulations Jul. 11, 2023
-
Patent Title: Viscosity-reducing excipient compounds for protein formulations Jun. 13, 2023
-
Patent Title: Viscosity-reducing excipient compounds for protein formulations May. 30, 2023
-
Patent Title: Excipient compounds for protein processing Jun. 14, 2022
Federal grants, loans, and purchases
Followers on CMRA's company Twitter account
Number of mentions of CMRA in WallStreetBets Daily Discussion
Recent insights relating to CMRA
Recent picks made for CMRA stock on CNBC
ETFs with the largest estimated holdings in CMRA
Flights by private jets registered to CMRA